BRAINSTORM CELL THERAPEUTICS INC. Stock Split Ratio
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) reported Stock Split Ratio of 6.70% for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Notes
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2026-03-31
- BRAINSTORM CELL THERAPEUTICS INC. stockholders' equity note, stock split, conversion ratio for the quarter ending 2025-03-31 was 6.70%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio | Stockholders' Equity Note, Stock Split, Conversion Ratio 3 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 6 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 9 month |
|---|---|---|---|---|
| 2025-09-30 | 6.70% 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | 6.70% 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | 6.70% 10-Q · filed 2025-05-15 | |||
| 2024-09-30 | 6.70% 10-K · filed 2026-03-31 | 6.70% 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |